Argenx has seen a range of developments related to its flagship antibody drug
Vyvgart. Notably, Argenx reported strong Q2 sales and expressed optimism for the drug's clinical plans, despite a slight pullback in Q4. The
FDA has approved Vyvgart to treat
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and
Generalized Myasthenia Gravis (gMG), granting the drug the first new treatment for CIDP in several decades. Additionally,
Zai Lab received approval to use
Argenx's Efgartigimod for gMG treatment in China. Several clinical trials for Argenx drugs have not met their primary endpoints, including a Phase III trial for Efgartigimod for Anti-neutrophil Cytoplasmic Autoantibody (ANCA)-Associated Vasculitis (AAV) and a study of an Argenx antibody in pemphigus. Despite these setbacks, Argenx remains committed to innovation in the autoimmune arena, evidenced by their ambitious
Vision 2030 plan and their reported year 2024 strategic priorities.
argenx News Analytics from Wed, 01 Nov 2023 07:00:00 GMT to Sat, 14 Sep 2024 13:04:23 GMT -
Rating 6
- Innovation 2
- Information 8
- Rumor -2